Anti-parietal cell autoantibodies (PCA) in primary biliarv cirrhosis: A putative marker for recurrence after orthotopic liver transplantation?

Annals of Hepatology

Volumn 9, Issue 2, 2010, Pages 181-185

  Ciesek, Sandra ^a   Becker, Thomas ^a   Manns, Michael P ^a   Strassburg, Christian P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Anti parietal cell autoantibodies; Autoantibodies; Orthotopic liver transplantation; PCA; Primary biliary cirrhosis

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BIOLOGICAL MARKER; CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MITOCHONDRION ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARIETAL CELL ANTIBODY; PREDNISOLONE; TACROLIMUS; AUTOANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CEREBROVASCULAR ACCIDENT; CHOLESTASIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; FEMALE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIMARY BILIARY CIRRHOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; SEPSIS; SEROLOGY; BILIARY CIRRHOSIS; BIOPSY; BLOOD; GERMANY; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PREDICTION AND FORECASTING; STOMACH PARIETAL CELL; TIME; TREATMENT OUTCOME;

ADULT; AGED; AUTOANTIBODIES; BIOLOGICAL MARKERS; BIOPSY; FEMALE; GERMANY; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PARIETAL CELLS, GASTRIC; PREDICTIVE VALUE OF TESTS; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 77956623552     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31659-x     Document Type: Article

References (21)

1. Schreibman I, Regev A. Recurrent primary biliary cirrhosis after liver transplantation-the disease and its management. MedGenMed 2006; 8(2): p. 30.
2. Donaldson P, et al. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility. Gut 2001; 48(3): p. 397-402.
3. Hopf U, et al. Relation between Escherichia coli R(rough)-forms in gut, lipid A in liver, and primary biliary cirrhosis. Lancet 1989; 2(8677): p. 1419-22.
4. Gershwin ME; Mackay IR. The causes of primary biliary cirrhosis: Convenient and inconvenient truths. Hepatology 2008; 47(2): p. 737-45.
5. Kumagi T, Heathcote EJ. Primary biliary cirrhosis. Orpha-net J Rare Dis 2008; 3: 1.
6. Strassburg CP, Manns MP. Autoimmune tests in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 2000; 14(4): 585-99.
7. Jacob DA, et al. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin Transplant 2006; 20(2): 211-20.
8. Guy JE, et al. Recurrent primary biliary cirrhosis: peri-transplant factors and ursodeoxycholic acid treatment post-liver transplant. Liver Transpl 2005; 11(10): 1252-7.
9. Van de Water J., et al. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis. N Engl J Med 1989; 320(21): 1377-80.
10. Walker JG, et al. Serological Tests In Diagnosis Of Primary Biliary Cirrhosis. Lancet 1965. 1: 827-31.
11. Neuberger J. Recurrent primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 2000; 14(4): 669-80.
12. Strassburg CP, et al. Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseases. J Hepatol 1996; 25(6): 859-66.
13. Strassburg CP, Jaeckel E, Manns MP. Anti-mitochondrial antibodies and other immunological tests in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999; 11(6): 595-601.
14. Strassburg CP, Manns MP. Autoantibodies and autoanti-gens in autoimmune hepatitis. Semin Liver Dis 2002; 22(4): 339-52.
15. Pellicano R, et al. Prevalence of non-organ-specific autoantibodies in patients suffering from duodenal ulcer with and without Helicobacter pylori infection. Dig Dis Sci 2004; 49(3): 395-8.
16. Parente F, et al. Presence of gastric autoantibodies impairs gastric secretory function in patients with Helicobacter pylori-positive duodenal ulcer. Scand J Gastroenterol 2001; 36(5): 474-8.
17. Claeys D, et al. The gastric H+,K+-ATPase is a major au-toantigen in chronic Helicobacter pylori gastritis with body mucosa atrophy. Gastroenterology 1998; 115(2): 340-7.
18. Faller G, et al. Evidence of novel pathogenic pathways for the formation of antigastric autoantibodies in Helicobacter pylori gastritis. J Clin Pathol 1998; 51(3): 244-5.
19. Annibale B, et al. Two-thirds of atrophic body gastritis patients have evidence of Helicobacter pylori infection. Helicobacter 2001; 6(3): 225-33.
20. Bergman MP, et al. The story so far: Helicobacter pylori and gastric autoimmunity. Int Rev Immunol 2005; 24(1-2): 63-91.
21. Durazzo M, et al. Lack of association between seropreva-lence of Helicobacter pylori infection and primary biliary cirrhosis. World J Gastroenterol 2004; 10(21): 3179-81.